Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Dean Li, president of Merck Research Laboratories, told the meeting that cardiovascular disease is a big opportunity as it remains an epidemic, killing 35 million people during the pandemic while ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

president of Merck Research Laboratories. "We continue to augment our oncology pipeline and look forward to working with the Kelun-Biotech team to advance these candidates to the patients that ...

Last year Merck agreed a similar licensing deal, also worth $2 billion, for Chinese biotech Hansoh Pharma’s experimental oral obesity drug, while yesterday Denmark’s Novo Nordisk (NVO) bought the ...

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together with berahyaluronidase alfa.

Merck complemented its 2010 acquisition of Millipore by acquiring Sigma-Aldrich for USD 17 billion in 2015, significantly expanding its Science and Lab Solutions portfolio and giving the company ...

(Bloomberg) -- Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion. Clover Biopharmaceuticals said Gavi sent notice of the termination of their ...

Merck Foundation marks World Cancer Day by providing 194 Oncology Scholarship to Doctors from 32 African Countries ...